See more : OneSoft Solutions Inc. (OSS.V) Income Statement Analysis – Financial Results
Complete financial analysis of Pasithea Therapeutics Corp. (KTTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pasithea Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Medallion Financial Corp. (MFIN) Income Statement Analysis – Financial Results
- Tricon Residential Inc. (TCN.TO) Income Statement Analysis – Financial Results
- Konica Minolta, Inc. (KNCAY) Income Statement Analysis – Financial Results
- China Holdings, Inc. (CHHL) Income Statement Analysis – Financial Results
- STEF SA (STF.PA) Income Statement Analysis – Financial Results
Pasithea Therapeutics Corp. (KTTA)
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 486.56K | 15.06K | 0.00 |
| Cost of Revenue | 648.45K | 113.20K | 17.28K | 0.00 |
| Gross Profit | -648.45K | 373.36K | -2.21K | 0.00 |
| Gross Profit Ratio | 0.00% | 76.74% | -14.69% | 0.00% |
| Research & Development | 8.10M | 2.67M | 0.00 | 0.00 |
| General & Administrative | 7.88B | 9.92M | 0.00 | 0.00 |
| Selling & Marketing | -7.87B | 2.60M | 0.00 | 0.00 |
| SG&A | 7.88M | 12.52M | 4.51M | 40.98K |
| Other Expenses | 0.00 | 44.72K | 0.00 | 0.00 |
| Operating Expenses | 15.98M | 15.19M | 4.51M | 40.98K |
| Cost & Expenses | 15.98M | 15.30M | 4.52M | 40.98K |
| Interest Income | 0.00 | 102.00 | 508.00 | 0.00 |
| Interest Expense | 0.00 | 102.00 | 508.00 | 0.00 |
| Depreciation & Amortization | 648.45K | 5.09K | 1.38K | 61.48K |
| EBITDA | -15.33M | -12.58M | -4.51M | 0.00 |
| EBITDA Ratio | 0.00% | -3,029.28% | -29,916.57% | 0.00% |
| Operating Income | -15.98M | -14.82M | -4.51M | -40.98K |
| Operating Income Ratio | 0.00% | -3,045.12% | -29,925.73% | 0.00% |
| Total Other Income/Expenses | 471.61K | 861.09K | 2.33M | -4.00 |
| Income Before Tax | -15.51M | -13.94M | -2.17M | -40.98K |
| Income Before Tax Ratio | 0.00% | -2,864.29% | -14,430.49% | 0.00% |
| Income Tax Expense | 0.00 | -879.97K | 508.00 | -61.48K |
| Net Income | -15.96M | -13.06M | -2.17M | -40.98K |
| Net Income Ratio | 0.00% | -2,683.43% | -14,433.87% | 0.00% |
| EPS | -12.65 | -10.34 | -1.89 | -0.06 |
| EPS Diluted | -13.01 | -10.34 | -1.89 | -0.06 |
| Weighted Avg Shares Out | 1.26M | 1.26M | 1.15M | 688.92K |
| Weighted Avg Shares Out (Dil) | 1.23M | 1.26M | 1.15M | 688.92K |
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
PALO ALTO, Calif. and MIAMI, Sept.
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
-- Attendees may request 1 x 1 meeting with management at [email protected] -- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery,...
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
-- PAS-003 is a monoclonal antibody targeting α 5/ β1 integrin for the treatment of amyotrophic lateral sclerosis (“ALS”) -- -- Lead α 5/ β1 integrin drug candidate to be selected in H2 2023 --
Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today...
Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.
Proposal Does Not Adequately Reflect Pasithea's Strategic Value and Prospects for Continued Growth Proposal Does Not Adequately Reflect Pasithea's Strategic Value and Prospects for Continued Growth
Hot Penny Stocks For Your January 2022 Watchlist
Making a penny stocks watchlist for January? Check these three out The post Hot Penny Stocks For Your January 2022 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Penny Stocks to Watch During Today's Bull Run
Can these three penny stocks continue to make gains next month? The post Top Penny Stocks to Watch During Today's Bull Run appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today
Pasithea Therapeutics (KTTA) stock is heading higher on heavy trading Thursday even without any recent news from the biotech company. The post KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today appeared first on InvestorPlace.
Pasithea Therapeutics (KTTA) Stock: Why The Price Jumped Today
The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 25% pre-market today. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports